Health
LCMC3 trial: Neoadjuvant atezolizumab prior to lung cancer surgery meets primary endpoint – News-Medical.Net
(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by…
(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer’s World Conference on Lung Cancer.
Dr. Jay M. Lee, chief, Division of Thoracic Surgery at Ronald Reagan UCLA Medical Center in Los Angeles, today reported on results…
-
General12 hours agoFarmers develop ‘autofill’ tech so agricultural robots can operate around the clock
-
Noosa News18 hours agoRevealed: 75 Qld suburbs you could afford to buy in if lending standards drop
-
General14 hours agoTrump mulling whether to fire US Fed chair Powell
-
Business15 hours agoThe easy way to build significant wealth with ASX shares